Tag: aduhelm
FDA Advisory Committee Recommends approval of new Alzheimer’s drug Donanemab
If approved, donanemab would be the third FDA approved disease-modifying beta-amyloid treatment for Alzheimer’s disease.
Congress criticizes the FDA and the Aduhelm approval
A Congressional report on the approval of the Alzheimer's drug Aduhelm identified serious concerns about the FDA's processes